These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 33010430)

  • 1. Myeloablative Conditioning for Allogeneic Transplantation Results in Superior Disease-Free Survival for Acute Myelogenous Leukemia and Myelodysplastic Syndromes with Low/Intermediate but not High Disease Risk Index: A Center for International Blood and Marrow Transplant Research Study.
    Bejanyan N; Zhang M; Bo-Subait K; Brunstein C; Wang H; Warlick ED; Giralt S; Nishihori T; Martino R; Passweg J; Dias A; Copelan E; Hale G; Gale RP; Solh M; Kharfan-Dabaja MA; Diaz MA; Ganguly S; Gore S; Verdonck LF; Hossain NM; Kekre N; Savani B; Byrne M; Kanakry C; Cairo MS; Ciurea S; Schouten HC; Bredeson C; Munker R; Lazarus H; Cahn JY; van Der Poel M; Rizzieri D; Yared JA; Freytes C; Cerny J; Aljurf M; Palmisiano ND; Pawarode A; Bacher VU; Grunwald MR; Nathan S; Wirk B; Hildebrandt GC; Seo S; Olsson RF; George B; de Lima M; Hourigan CS; Sandmaier BM; Litzow M; Kebriaei P; Saber W; Weisdorf D
    Transplant Cell Ther; 2021 Jan; 27(1):68.e1-68.e9. PubMed ID: 33010430
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Dilemma of Conditioning Intensity: When Does Myeloablative Conditioning Improve Outcomes for Allogeneic Hematopoietic Cell Transplantation.
    Solh MM; Solomon SR; Morris LE; Zhang X; Holland HK; Bashey A
    Biol Blood Marrow Transplant; 2019 Mar; 25(3):606-612. PubMed ID: 30244109
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Myeloablative versus Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation in Acute Myelogenous Leukemia and Myelodysplastic Syndromes-Long-Term Follow-Up of the BMT CTN 0901 Clinical Trial.
    Scott BL; Pasquini MC; Fei M; Fraser R; Wu J; Devine SM; Porter DL; Maziarz RT; Warlick E; Fernandez HF; Soiffer RJ; Alyea E; Hamadani M; Bashey A; Giralt S; Geller NL; Leifer E; Hourigan CS; Gui G; Mendizabal A; Horowitz MM; Deeg HJ; Horwitz ME
    Transplant Cell Ther; 2021 Jun; 27(6):483.e1-483.e6. PubMed ID: 33775615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD34
    Barba P; Martino R; Zhou Q; Cho C; Castro-Malaspina H; Devlin S; Esquirol A; Giralt S; Jakubowski AA; Caballero D; Maloy M; Papadopoulos EB; Piñana JL; Fox ML; Márquez-Malaver FJ; Valcárcel D; Solano C; López-Corral L; Sierra J; Perales MA
    Biol Blood Marrow Transplant; 2018 May; 24(5):964-972. PubMed ID: 29305194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allogeneic Transplantation to Treat Therapy-Related Myelodysplastic Syndrome and Acute Myelogenous Leukemia in Adults.
    Metheny L; Callander NS; Hall AC; Zhang MJ; Bo-Subait K; Wang HL; Agrawal V; Al-Homsi AS; Assal A; Bacher U; Beitinjaneh A; Bejanyan N; Bhatt VR; Bredeson C; Byrne M; Cairo M; Cerny J; DeFilipp Z; Perez MAD; Freytes CO; Ganguly S; Grunwald MR; Hashmi S; Hildebrandt GC; Inamoto Y; Kanakry CG; Kharfan-Dabaja MA; Lazarus HM; Lee JW; Nathan S; Nishihori T; Olsson RF; Ringdén O; Rizzieri D; Savani BN; Savoie ML; Seo S; van der Poel M; Verdonck LF; Wagner JL; Yared JA; Hourigan CS; Kebriaei P; Litzow M; Sandmaier BM; Saber W; Weisdorf D; de Lima M
    Transplant Cell Ther; 2021 Nov; 27(11):923.e1-923.e12. PubMed ID: 34428556
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Measurable residual disease, conditioning regimen intensity, and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: A registry analysis of 2292 patients by the Acute Leukemia Working Party European Society of Blood and Marrow Transplantation.
    Gilleece MH; Labopin M; Yakoub-Agha I; Volin L; Socié G; Ljungman P; Huynh A; Deconinck E; Wu D; Bourhis JH; Cahn JY; Polge E; Mohty M; Savani BN; Nagler A
    Am J Hematol; 2018 Sep; 93(9):1142-1152. PubMed ID: 29981272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes.
    Scott BL; Pasquini MC; Logan BR; Wu J; Devine SM; Porter DL; Maziarz RT; Warlick ED; Fernandez HF; Alyea EP; Hamadani M; Bashey A; Giralt S; Geller NL; Leifer E; Le-Rademacher J; Mendizabal AM; Horowitz MM; Deeg HJ; Horwitz ME
    J Clin Oncol; 2017 Apr; 35(11):1154-1161. PubMed ID: 28380315
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia.
    Chen YB; Coughlin E; Kennedy KF; Alyea EP; Armand P; Attar EC; Ballen KK; Cutler C; Dey BR; Koreth J; McAfee SL; Spitzer TR; Antin JH; Soiffer RJ; Ho VT
    Biol Blood Marrow Transplant; 2013 Jun; 19(6):981-7. PubMed ID: 23562738
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome using treosulfan based compared to other reduced-intensity or myeloablative conditioning regimens. A report of the chronic malignancies working party of the EBMT.
    Shimoni A; Robin M; Iacobelli S; Beelen D; Mufti GJ; Ciceri F; Bethge W; Volin L; Blaise D; Ganser A; Luft T; Chevallier P; Schwerdtfeger R; Koster L; de Witte T; Kröger N; Nagler A; Yakoub-Agha I
    Br J Haematol; 2021 Nov; 195(3):417-428. PubMed ID: 34514596
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of Myeloablative versus Reduced-Intensity Conditioning Regimens in Allogeneic Stem Cell Transplantation Recipients with Acute Myelogenous Leukemia with Measurable Residual Disease-Negative Disease at the Time of Transplantation: A Retrospective Cohort Study.
    Yu J; Du Y; Ahmad S; Patel RD; Varela JC; Chang CC; Mori S
    Transplant Cell Ther; 2021 Aug; 27(8):663.e1-663.e6. PubMed ID: 33951497
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term survival and late events after allogeneic stem cell transplantation from HLA-matched siblings for acute myeloid leukemia with myeloablative compared to reduced-intensity conditioning: a report on behalf of the acute leukemia working party of European group for blood and marrow transplantation.
    Shimoni A; Labopin M; Savani B; Volin L; Ehninger G; Kuball J; Bunjes D; Schaap N; Vigouroux S; Bacigalupo A; Veelken H; Sierra J; Eder M; Niederwieser D; Mohty M; Nagler A
    J Hematol Oncol; 2016 Nov; 9(1):118. PubMed ID: 27821187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Art of Transplantation: Conditioning Intensity for Allogeneic Hematopoietic Stem Cell Transplantation.
    Ragon BK
    Biol Blood Marrow Transplant; 2019 Mar; 25(3):e71-e72. PubMed ID: 30562588
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of conditioning intensity in T-replete haplo-identical stem cell transplantation for acute leukemia: a report from the acute leukemia working party of the EBMT.
    Rubio MT; Savani BN; Labopin M; Piemontese S; Polge E; Ciceri F; Bacigalupo A; Arcese W; Koc Y; Beelen D; Gülbas Z; Wu D; Santarone S; Tischer J; Afanasyev B; Schmid C; Giebel S; Mohty M; Nagler A
    J Hematol Oncol; 2016 Mar; 9():25. PubMed ID: 26980295
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conditioning intensity in secondary AML with prior myelodysplastic syndrome/myeloproliferative disorders: an EBMT ALWP study.
    Sengsayadeth S; Gatwood KS; Boumendil A; Labopin M; Finke J; Ganser A; Stelljes M; Ehninger G; Beelen D; Niederwieser D; Blaise D; Dreger P; Mufti G; Chevallier P; Mailhol A; Gilleece MH; Gorin N; Esteve J; Ciceri F; Baron F; Schmid C; Giebel S; Mohty M; Savani BN; Nagler A
    Blood Adv; 2018 Aug; 2(16):2127-2135. PubMed ID: 30143527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Myeloablative, but not Reduced-Intensity, Conditioning Overcomes the Negative Effect of Flow-Cytometric Evidence of Leukemia in Acute Myeloid Leukemia.
    Ustun C; Courville EL; DeFor T; Dolan M; Randall N; Yohe S; Bejanyan N; Warlick E; Brunstein C; Weisdorf DJ; Linden MA
    Biol Blood Marrow Transplant; 2016 Apr; 22(4):669-675. PubMed ID: 26551635
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of reduced-intensity and myeloablative conditioning regimens for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia and acute lymphoblastic leukemia: a meta-analysis.
    Abdul Wahid SF; Ismail NA; Mohd-Idris MR; Jamaluddin FW; Tumian N; Sze-Wei EY; Muhammad N; Nai ML
    Stem Cells Dev; 2014 Nov; 23(21):2535-52. PubMed ID: 25072307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose-Reduced Versus Standard Conditioning Followed by Allogeneic Stem-Cell Transplantation for Patients With Myelodysplastic Syndrome: A Prospective Randomized Phase III Study of the EBMT (RICMAC Trial).
    Kröger N; Iacobelli S; Franke GN; Platzbecker U; Uddin R; Hübel K; Scheid C; Weber T; Robin M; Stelljes M; Afanasyev B; Heim D; Deliliers GL; Onida F; Dreger P; Pini M; Guidi S; Volin L; Günther A; Bethge W; Poiré X; Kobbe G; van Os M; Brand R; de Witte T
    J Clin Oncol; 2017 Jul; 35(19):2157-2164. PubMed ID: 28463633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conditioning intensity in middle-aged patients with AML in first CR: no advantage for myeloablative regimens irrespective of the risk group-an observational analysis by the Acute Leukemia Working Party of the EBMT.
    Passweg JR; Labopin M; Cornelissen J; Volin L; Socié G; Huynh A; Tabrizi R; Wu D; Craddock C; Schaap N; Kuball J; Chevallier P; Cahn JY; Blaise D; Ghavamzadeh A; Bilger K; Ciceri F; Schmid C; Giebel S; Nagler A; Mohty M;
    Bone Marrow Transplant; 2015 Aug; 50(8):1063-8. PubMed ID: 26030052
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic impact of the conditioning intensity on outcomes after allogeneic transplantation for MDS with low blasts: a nationwide retrospective study by the adult MDS working group of the Japan Society for Transplantation and Cellular Therapy.
    Itonaga H; Miyazaki Y; Fujioka M; Aoki J; Doki N; Nishida T; Fukuda T; Uchida N; Ueda Y; Uehara Y; Katayama Y; Ota S; Kawakita T; Kato J; Matsuoka KI; Eto T; Onizuka M; Ichinohe T; Atsuta Y; Ishiyama K
    Bone Marrow Transplant; 2024 Aug; 59(8):1107-1117. PubMed ID: 38714756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome.
    McClune BL; Weisdorf DJ; Pedersen TL; Tunes da Silva G; Tallman MS; Sierra J; Dipersio J; Keating A; Gale RP; George B; Gupta V; Hahn T; Isola L; Jagasia M; Lazarus H; Marks D; Maziarz R; Waller EK; Bredeson C; Giralt S
    J Clin Oncol; 2010 Apr; 28(11):1878-87. PubMed ID: 20212255
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.